64 completed, 12 terminated, 5 unknown, 4 recruiting. 43 Phase 2, 36 Phase 3, 9 Phase 1, 4 Phase 4, 3 Not applicable.
Follow Premier Research: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle FB-301, Placebo, Chlorhexidine (0.5%) Vaginal Cleanse - Vaginal Dysbiosis | Phase 2 | Recruiting | Freya Biosciences ApS | 30 | 2026-07-22 | 2026-10-15 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception Levonorgestrel butanoate - Healthy Women, Female Contraception | Phase 2 | Not yet recruiting | Premier Research | 165 | 2026-04-01 | 2025-10-29 |
| An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study) SPT-300 - Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress | Phase 2 | Enrolling by invitation | Seaport Therapeutics | 360 | 2025-09-02 | 2026-11-10 |
| Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder BXCL501 Sublingual Film - Bipolar I Disorder, Bipolar II Disorder | Phase 2 | Completed | BioXcel Therapeutics Inc | 33 | 2025-06-19 | 2026-10-05 |
| A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) SPT-300, Placebo - Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress | Phase 2 | Recruiting | Seaport Therapeutics | 360 | 2025-06-19 | 2026-11-10 |
| A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) INT230-6, Eribulin, Trabectedin - Sarcoma,Soft Tissue | Phase 3 | Recruiting | Intensity Therapeutics, Inc. | 333 | 2024-06-28 | 2026-08-11 |
| Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients Amisulpride Injection, Dexamethasone - Nausea and Vomiting, Postoperative | Phase 2 / Phase 3 | Completed | Acacia Pharma Ltd | 453 | 2024-01-18 | 2025-06-25 |
| HEM1036 Phase 2 Study in Low Anterior Resection Syndrome Lactobacillus Fermentum, Placebo - LARS - Low Anterior Resection Syndrome | Phase 2 | Unknown | HEM Pharma Inc. | 67 | 2024-01-01 | 2023-05-25 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia RLS-0071, Placebo - Hypoxic-Ischemic Encephalopathy | Phase 2 / Phase 3 | Recruiting | ReAlta Life Sciences, Inc. | 173 | 2023-07-27 | 2026-11-05 |
| Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency) Tiratricol, Placebo - Monocarboxylate Transporter 8 Deficiency, Allan-Herndon-Dudley Syndrome | Phase 3 | Completed | Rare Thyroid Therapeutics International AB | 20 | 2023-07-21 | 2026-04-08 |
| A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) - Attention Deficit/Hyperactivity Disorder | Phase 4 | Completed | Corium, Inc. | 123 | 2023-06-02 | 2026-05-08 |
| The Purpose of This Study is to Assess Clinical Efficacy and Safety of Berovenal® Intended to Promote Treatment and to Expedite Chronic Diabetic Foot Ulcer Healing Berovenal®, NU-GEL Hydrogel with Alginate - Diabetic Foot Ulcer | Not applicable | Unknown | VULM s.r.o. | 66 | 2023-05-17 | 2024-09-05 |
| An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo - Attention Deficit/Hyperactivity Disorder | Phase 4 | Completed | Corium, Inc. | 246 | 2023-03-22 | 2025-05-13 |
| The Effectiveness of Sustained Heat Treatment on Delayed-Onset Muscle Soreness (DOMS) ThermaCare HeatWraps - Delayed-Onset Muscle Soreness (DOMS) | Not applicable | Completed | Aziende Chimiche Riunite Angelini Francesco S.p.A | 102 | 2023-01-30 | 2024-04-04 |
| A Trial to Determine the Efficacy and Safety of Presendin in IIH Presendin, Placebo - Idiopathic Intracranial Hypertension | Phase 3 | Terminated | Invex Therapeutics Ltd. | 14 | 2022-11-18 | 2024-04-24 |
| Ibuprofen Liquid Capsules 2 x 200 mg Efficacy and PK/PD Study in Surgical Removal of Impacted Third Molars Ibuprofen 200Mg Oral Cap, Ibuprofen 200Mg Oral Tablet, Placebo Liquid Capsule - Tooth, Impacted, Tooth Diseases | Phase 3 | Completed | Reckitt Benckiser Healthcare (UK) Limited | 294 | 2022-08-09 | 2023-06-22 |
| The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents Bonjesta, Placebo - Morning Sickness | Phase 3 | Suspended | Duchesnay Inc. | 274 | 2022-05-01 | 2026-04-03 |
| Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens TNX-2110, TNX-2120, TNX-2130 - Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2 | Phase 1 | Terminated | Tonix Pharmaceuticals, Inc. | 9 | 2022-01-07 | 2024-11-06 |
| Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease Simufilam, Placebo - Alzheimer Disease | Phase 3 | Terminated | Cassava Sciences, Inc. | 1125 | 2021-11-18 | 2025-09-22 |
| Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease Simufilam, Placebo - Alzheimer Disease | Phase 3 | Completed | Cassava Sciences, Inc. | 804 | 2021-11-03 | 2025-05-25 |
Showing 20 of 92. Sign in to see all of them.
Pain, Postoperative (12) · Attention Deficit Disorder with Hyperactivity (4) · Diabetic Foot (4) · Diabetes Mellitus (3) · Hernia, Inguinal (3) · Nausea (3) · Pain (3) · Stress Disorders, Post-Traumatic (3) · Vomiting (3) · Acute Pain (2) · Alzheimer Disease (2) · Anxiety Disorders (2) · Colorectal Neoplasms (2) · Depression (2) · Depressive Disorder (2)
remimazolam (5) · Bupivacaine (4) · Midazolam (4) · Ibuprofen (3) · ST 1435 (3) · Sodium Chloride (3) · levonorgestrel butanoate (3) · BufferGel (2) · Dexmethylphenidate Hydrochloride (2) · Levofloxacin (2) · Nonoxynol (2) · Simufilam (2) · Tablets (2) · dicyclomine, doxylamine, pyridoxine drug combination (2) · ulipristal acetate (2)
United States (81) · Germany (9) · United Kingdom (8) · France (7) · Spain (7) · Canada (6) · Australia (4) · Italy (4) · Netherlands (4) · Poland (4) · Belgium (3) · Hungary (3) · Slovakia (3) · Bulgaria (2) · Czechia (2)
David Prior (11) · Ann Childress, MD (3) · Christina Wang, MD (2) · David Walling, Ph.D. (2) · Diana Blithe (2) · Diana Blithe, PhD (2) · James Kupiec, MD (2) · Todd Bertoch, MD (2) · Alison Edelman, MD (1) · Andrew J. Bauer, MD (1) · Andrew J. Cutler, MD (1) · Anita L Nelson, MD (1) · Atul R Mahableshwarkar, MD, DFAPA (1) · BioXcel MM (1) · Carolyn R Sikes, PhD (1)
PMID 22792007, PMID 41500915, PMID 17766603, PMID 20716738, PMID 20825316, PMID 20843504, PMID 21099590, PMID 22659765, PMID 22972538, PMID 23152696, PMID 23390367, PMID 25052410, PMID 25502841, PMID 25884778, PMID 26267119, PMID 26363333, PMID 26844757, PMID 26874076, PMID 27881103, PMID 29342163, PMID 29723512, PMID 30252057, PMID 30292760, PMID 30849305, PMID 31231065, PMID 31381878, PMID 31398307, PMID 31976519, PMID 32168217, PMID 33587394, PMID 33908182, PMID 33970869, PMID 35857716, PMID 35865736, PMID 36347310, PMID 38295968, PMID 38350291, PMID 38477985, PMID 38477993, PMID 39316284, PMID 40314885, PMID 40693846
2025 (2), 2009 (1), 2015 (1), 2016 (1)